Greenwich LifeSciences Reports $3.9 Million Net Loss in Q2 2026, Increases R&D Spending

Greenwich LifeSciences, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $3.9 million for the three months ended June 30, compared to a loss of $3.7 million during the same period in 2025. For the first half of 2026, the company recorded a net loss of approximately $9.6 million, up from $6.5 million in the prior year. The increase in losses is attributed primarily to higher research and development expenses, which rose by 4% to $3.6 million in the second quarter and by 54% to $8.8 million for the six-month period, driven by increased clinical expenses and stock option grants.

As of June 30, 2026, Greenwich LifeSciences reported total assets of $8.9 million, a significant increase from $6.2 million at the end of 2025. The company's cash position improved to $8.9 million, up from $6.2 million, reflecting successful capital-raising efforts through At The Market (ATM) offerings. During the first half of 2026, the company raised approximately $9.3 million from the sale of 379,762 shares at an average price of $25.36 per share, compared to $3.1 million raised from 320,210 shares sold at an average price of $9.95 per share in the same period of 2025.

The company continues to focus on its Phase III clinical trial, Flamingo-01, which evaluates GLSI-100, an immunotherapy aimed at preventing breast cancer recurrence. Greenwich LifeSciences is expanding this trial into Europe, with plans to open up to 150 sites globally. The company has not generated any revenue to date, and its operational strategy remains heavily reliant on securing additional capital to fund ongoing clinical trials and operational expenses.

In terms of operational metrics, the company had 14,678,208 shares of common stock outstanding as of June 30, 2026, an increase from 14,298,446 shares at the end of 2025. The increase in shares reflects the company's ongoing efforts to raise capital through equity offerings. The company has also noted that it is classified as a smaller reporting company and a non-accelerated filer, which allows it to take advantage of certain regulatory exemptions.

Looking ahead, Greenwich LifeSciences anticipates continued net losses as it invests in the development of its clinical pipeline and infrastructure. The company has expressed the need for additional capital to support its long-term operating requirements and plans to raise funds through equity and/or debt securities. The management remains focused on advancing its clinical trials and preparing for potential commercialization of its product candidate, while also addressing the challenges associated with being a public company.